Antibodies, essential components in many current therapies, have traditionally been limited to targeting structures on the surface of cells. Recent advancements now allow for the re-engineering of antibodies to function intracellularly, offering potential new treatments for diseases that originate within cells, particularly neurodegenerative disorders like Alzheimer’s and Parkinson’s.
A significant challenge has been the stability of antibody fragments once inside the cell, where they often misfold or aggregate due to the differing chemical environment. To address this, researchers employed artificial intelligence to redesign antibody fragments, focusing on their stability and functionality within cells. This process led to the creation of over 600 new, stable intracellular antibody fragments that maintain their ability to recognize specific disease-related targets.
This innovative approach optimizes the charge distribution of these fragments, preventing them from clumping together and allowing them to move freely within the cell. The redesigned fragments can specifically identify and bind to harmful proteins associated with neurodegenerative diseases, which accumulate inside cells and disrupt normal function. This precision is crucial, as misdirected treatments could further impair cellular processes.
The re-engineered antibodies align with emerging gene-based delivery technologies, potentially enabling cells to produce these therapeutic fragments internally. This dual approach enhances the targeting of intracellular processes, opening new pathways for treatment in a range of conditions beyond neurodegenerative diseases, including cancer and inflammatory disorders.
In summary, advancements in antibody design, guided by artificial intelligence, mark a significant evolution in therapeutic strategies, expanding the potential for targeted treatments at the cellular level and paving the way for future innovations in biotechnology.